Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies

Antibody-drug conjugates (ADCs) improve targeted drug delivery but are often associated with hematological toxicity. This review examines the structural, mechanistic and clinical evidence on ADC-induced hematological toxicity, focusing on approved ADCs and strategies for dose adjustment. Approved ADCs, including Gemtuzumab Ozogamicin (GO), Inotuzumab Ozogamicin (IO), trastuzumab emtansine, brentuximab vedotin, Polatuzumab Vedotin (PV), Sacituzumab Govitecan (SG), trastuzumab deruxtecan, Enfortumab Vedotin (EV), tisotumab vedotin, Loncastuximab Tesirine (LT), belantamab mafodotin, mirvetuximab soravtansine and disitamab vedotin, exhibit distinct hematological toxicity profiles. Common adverse events include neutropenia, thrombocytopenia, anemia, leukopenia, lymphopenia and febrile neutropenia. These toxicities are influenced by factors such as antigen distribution, linker stability, payload characteristics, drug-to-antibody ratio, Fc receptor-mediated uptake and nonspecific endocytosis. Management strategies include dose interruption or reduction, growth factor support, transfusions and regular laboratory monitoring. Hematological toxicity is an important factor affecting the tolerability of ADCs. Understanding the mechanisms underlying these toxicities is essential for improving their clinical management and guiding the development of safer next-generation ADCs.

Authors

Publication Details

Journal
Pharmacology and Toxicology Research
Published
2026-11-13
DOI
https://doi.org/10.68163/ptr.2026.76
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies

Jaini Patel, Samarth R Rathod, Amar M. Raval, DR. AASTHA UKANI et al.
4 links
Pharmacology and Toxicology Research
Monoclonal and Polyclonal Antibodies Research
article

Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies

Jaini Patel, Samarth R Rathod, Amar M. Raval, DR. AASTHA UKANI, Ashok Kumar
article en

Abstract

Antibody-drug conjugates (ADCs) improve targeted drug delivery but are often associated with hematological toxicity. This review examines the structural, mechanistic and clinical evidence on ADC-induced hematological toxicity, focusing on approved ADCs and strategies for dose adjustment. Approved ADCs, including Gemtuzumab Ozogamicin (GO), Inotuzumab Ozogamicin (IO), trastuzumab emtansine, brentuximab vedotin, Polatuzumab Vedotin (PV), Sacituzumab Govitecan (SG), trastuzumab deruxtecan, Enfortumab Vedotin (EV), tisotumab vedotin, Loncastuximab Tesirine (LT), belantamab mafodotin, mirvetuximab soravtansine and disitamab vedotin, exhibit distinct hematological toxicity profiles. Common adverse events include neutropenia, thrombocytopenia, anemia, leukopenia, lymphopenia and febrile neutropenia. These toxicities are influenced by factors such as antigen distribution, linker stability, payload characteristics, drug-to-antibody ratio, Fc receptor-mediated uptake and nonspecific endocytosis. Management strategies include dose interruption or reduction, growth factor support, transfusions and regular laboratory monitoring. Hematological toxicity is an important factor affecting the tolerability of ADCs. Understanding the mechanisms underlying these toxicities is essential for improving their clinical management and guiding the development of safer next-generation ADCs.

Pharmacology and Toxicology ResearchVol. 2
Good health and well-being
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon